Alba A Brandes Selected Research

Alba A Brandes Research Topics

Disease

60	Neoplasms (Cancer) 10/2022 - 05/2002
59	Glioblastoma (Glioblastoma Multiforme) 04/2022 - 01/2002
28	Glioma (Gliomas) 01/2021 - 05/2002
17	Disease Progression 01/2020 - 02/2003
13	Brain Neoplasms (Brain Tumor) 10/2022 - 05/2002
9	Oligodendroglioma 01/2019 - 06/2006
8	Breast Neoplasms (Breast Cancer) 11/2020 - 09/2004
8	Medulloblastoma 01/2020 - 10/2003
7	Astrocytoma (Pilocytic Astrocytoma) 01/2022 - 12/2003
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017 - 05/2009
3	Lymphoma (Lymphomas) 01/2020 - 10/2009
3	Cognitive Dysfunction 01/2019 - 05/2004
3	Neoplasm Metastasis (Metastasis) 09/2017 - 10/2004
2	Pituitary Neoplasms (Pituitary Adenoma) 01/2022 - 01/2020
2	Meningioma (Meningiomas) 01/2021 - 01/2020
2	Lymphopenia (Lymphocytopenia) 01/2021 - 09/2014
2	Vomiting 01/2020 - 12/2007
2	Nausea 01/2020 - 12/2007
2	Necrosis 11/2019 - 11/2013
2	Adenocarcinoma of Lung 01/2017 - 01/2017
2	Fatigue 11/2016 - 05/2015
2	Colorectal Neoplasms (Colorectal Cancer) 05/2016 - 05/2014
2	Neutropenia 05/2015 - 09/2014
1	Central Nervous System Neoplasms 01/2022
1	Adenoma (Adenomas) 01/2022
1	Seizures (Absence Seizure) 08/2020
1	Epilepsy (Aura) 08/2020
1	Spinal Cord Neoplasms (Spinal Cord Tumors) 01/2020
1	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2020
1	Head and Neck Neoplasms (Head and Neck Cancer) 12/2017
1	Primary Ovarian Insufficiency 05/2017
1	Infertility (Sterility) 05/2017
1	Virus Diseases (Viral Diseases) 11/2016
1	HIV Infections (HIV Infection) 11/2016

Drug/Important Bio-Agent (IBA)

48	Temozolomide (Temodar)FDA LinkGeneric 04/2022 - 01/2002
19	Bevacizumab (Avastin)FDA Link 01/2022 - 10/2009
18	Lomustine (CCNU)FDA Link 10/2022 - 02/2003
12	Procarbazine (Matulane)FDA Link 10/2022 - 01/2002
12	Vincristine (Oncovin)FDA LinkGeneric 10/2022 - 01/2002
9	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2003
9	Biological ProductsIBA 01/2020 - 02/2007
7	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2022 - 11/2013
6	Trastuzumab (Herceptin)FDA Link 11/2020 - 08/2007
6	MethyltransferasesIBA 04/2018 - 10/2006
5	ErbB Receptors (EGF Receptor)IBA 01/2017 - 02/2008
5	Pharmaceutical PreparationsIBA 06/2015 - 10/2002
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2014 - 02/2007
4	NivolumabIBA 04/2022 - 12/2017
3	Hormones (Hormone)IBA 11/2020 - 09/2004
3	Monoclonal AntibodiesIBA 09/2017 - 12/2009
3	Angiogenesis InhibitorsIBA 08/2017 - 05/2011
3	DNA (Deoxyribonucleic Acid)IBA 10/2016 - 10/2006
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2014 - 03/2009
2	pembrolizumabIBA 01/2022 - 12/2017
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
2	MicroRNAs (MicroRNA)IBA 11/2021 - 11/2015
2	taxaneIBA 11/2020 - 06/2015
2	PlatinumIBA 12/2017 - 05/2015
2	LY-2157299IBA 05/2017 - 01/2016
2	Phosphotransferases (Kinase)IBA 05/2017 - 01/2016
2	Transforming Growth Factors (Transforming Growth Factor)IBA 05/2017 - 01/2016
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2017 - 02/2007
2	Tyrosine Kinase InhibitorsIBA 01/2017 - 02/2010
2	fotemustine (Muphoran)IBA 01/2016 - 09/2009
2	Lapatinib (GW572016)FDA Link 11/2013 - 02/2010
2	O-(6)-methylguanineIBA 03/2010 - 10/2006
2	Carmustine (FIVB)FDA Link 03/2009 - 12/2004
2	Imatinib Mesylate (Gleevec)FDA Link 10/2008 - 12/2003
2	Cisplatin (Platino)FDA LinkGeneric 07/2005 - 05/2004
2	thiamine triphosphorate (TTP)IBA 02/2003 - 01/2002
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2022
1	Growth Hormone (Somatotropin)IBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2022
1	IpilimumabIBA 01/2022
1	GadoliniumIBA 12/2021
1	Contrast MediaIBA 12/2021
1	regorafenibIBA 01/2021
1	AnthracyclinesIBA 11/2020
1	Biological FactorsIBA 11/2019
1	Indicators and Reagents (Reagents)IBA 01/2019
1	human ERBB2 proteinIBA 12/2018
1	Codon (Codons)IBA 01/2018
1	Genetic Markers (Genetic Marker)IBA 01/2018
1	AntibodiesIBA 12/2017
1	sonidegibIBA 10/2017
1	Glial Fibrillary Acidic ProteinIBA 05/2017
1	Chemokine CCL22IBA 05/2017
1	LigandsIBA 01/2017
1	onartuzumabIBA 01/2017
1	Gefitinib (Iressa)FDA Link 01/2017

Therapy/Procedure

51	Radiotherapy 10/2022 - 01/2002
47	Drug Therapy (Chemotherapy) 10/2022 - 05/2002
31	Therapeutics 11/2020 - 05/2002
5	Chemoradiotherapy 01/2020 - 05/2008
4	Adjuvant Chemotherapy 12/2007 - 02/2003
3	Immunotherapy 12/2017 - 11/2015
3	Salvage Therapy 09/2009 - 07/2005
2	Adjuvant Radiotherapy 01/2021 - 03/2005
2	Aftercare (After-Treatment) 01/2020 - 12/2007